Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
Clinical trial NCT03933761 · WITHDRAWN
Trial details
- NCT number
- NCT03933761
- Sponsor
- Australia New Zealand Gynaecological Oncology Group
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-29
- Primary completion
- 2021-08-02
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.